Small-molecule inhibition of Poly (ADP-ribose) polymerase 1 and 2 (PARP1/2) is an approved therapeutic strategy for the treatment of metastatic breast, ovarian, pancreatic and prostate cancers associated with Homologous Recombination (HR) defects, including mutations in BRCA1 gene. Here, PARP1 is linked to prostate cancer.